Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity in a report released on Tuesday.
A number of other research analysts have also commented on the company. Barclays PLC assumed coverage on Ultragenyx Pharmaceutical in a report on Wednesday, September 6th. They set an “equal weight” rating and a $60.00 price target for the company. Jefferies Group LLC set a $62.00 target price on Ultragenyx Pharmaceutical and gave the company a “hold” rating in a research note on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, August 23rd. JMP Securities cut their target price on Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 23rd. Finally, Morgan Stanley restated an “equal weight” rating and issued a $69.00 target price (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. Ultragenyx Pharmaceutical has an average rating of “Hold” and a consensus price target of $74.00.
Ultragenyx Pharmaceutical (RARE) traded down 0.48% during trading on Tuesday, reaching $50.27. 301,941 shares of the company’s stock were exchanged. The company’s market capitalization is $2.13 billion. The stock’s 50-day moving average price is $59.39 and its 200-day moving average price is $64.37. Ultragenyx Pharmaceutical has a 52-week low of $49.56 and a 52-week high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.01. During the same period last year, the business earned ($1.46) EPS. Equities analysts expect that Ultragenyx Pharmaceutical will post ($7.21) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Given Buy Rating at Canaccord Genuity” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2887381/ultragenyx-pharmaceutical-inc-rare-given-buy-rating-at-canaccord-genuity.html.
In related news, CEO Emil D. Kakkis purchased 7,500 shares of the stock in a transaction on Monday, August 28th. The shares were purchased at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 9.20% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. FMR LLC grew its position in Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock valued at $414,178,000 after acquiring an additional 227,802 shares during the period. Capital Research Global Investors grew its position in Ultragenyx Pharmaceutical by 1.4% in the second quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock valued at $321,937,000 after acquiring an additional 71,811 shares during the period. BlackRock Inc. grew its position in Ultragenyx Pharmaceutical by 10.4% in the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock valued at $217,237,000 after acquiring an additional 330,911 shares during the period. Vanguard Group Inc. grew its position in Ultragenyx Pharmaceutical by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock valued at $194,421,000 after acquiring an additional 135,335 shares during the period. Finally, Capital International Investors grew its position in Ultragenyx Pharmaceutical by 9.1% in the second quarter. Capital International Investors now owns 2,374,985 shares of the biopharmaceutical company’s stock valued at $147,510,000 after acquiring an additional 198,252 shares during the period. Hedge funds and other institutional investors own 96.18% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.